ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
IDM Pharma Presents Preliminary Results From Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial
IDM Pharma, Inc.
(Nasdaq: IDMI) today presented preliminary results from a Phase II UVIDEM
(IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed
that UVIDEM was well tolerated with evidence of efficacy and induction of
immune response in patients with progressive metastatic melanoma.
The data were presented by Merrick I. Ross, M.D., Professor of Surgery,
Chief, Melanoma Section, Department of Surgical Oncology at The University
of Texas M. D. Anderson Cancer Center in Houston as an oral presentation
titled "Clinical and immunological responses in patients with malignant
melanoma treated with a dendritic cell-based vaccine. Preliminary report
from a multi- institutional phase II clinical trial" (# 3004) at the 2007
American Society of Clinical Oncology (ASCO) 43rd annual meeting in
Chicago.
"We are in great need of new drugs to treat our patients with
metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase
II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that
several patients with advanced melanoma attained durable control of their
disease after a treatment stimulating their own immune system cells.
Additionally, the side effects experienced by our patients were minimal,"
he added.
Study design and findings
DC-MEL-202 is a single arm, two-stage Phase II trial designed to
evaluate clinical and immunological activities and the safety of a
multivalent dendritic cell-based vaccine in patients with in-transit or low
volume metastatic melanoma. Thirty-three patients were treated in the study
and the results to date are as follows:
-- Clinical response (RECIST): out of 30 patients evaluable for efficacy,
9 (30%) showed evidence of clinical benefit (1 complete response (CR),
2 partial responses (PR) and 6 stable disease (SD)) with duration of
response ranging from 9.4 to 26.5 months.
-- Assessment of pathological response in target sites in 4 patients (2
PR, 2 SD) showed:
-- complete pathological regression after resection of target sites
in 2 patients; and
-- two patients were rendered free of disease after clinical stable
disease and surgery of lung metastases.
-- Progression free survival (PFS) was 4.8 months with a median follow-up
of 12 months.
-- Overall survival (OS) has not yet been reached as 21 patients are
still alive. The survival rate at 9 months was 70%.
-- Immune response: 26 out of 29 evaluated patients (90%) showed
detectable TAA-specific CD8+ T cells with 18 patients (62%) showing
boosted or appearance of anti-TAA specific CD8+ T cells.
-- UVIDEM was well tolerated with toxicity limited to mild events with
only one possibly related serious adverse event (SAE) reported (age
related macular degeneration).
About UVIDEM
UVIDEM is a therapeutic specific immunostimulant developed by IDM
Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide
marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic
cells loaded with lysates from melanoma tumor cell lines. UVIDEM is
produced in IDM Pharma GMP manufacturing facilities in Irvine, California
and in Paris, France. UVIDEM has been administered to 143 patients in
clinical development. Completion of patient enrollment in two Phase II
clinical trials was previously announced. Thirty-eight patients with
malignant melanoma were included in the US Phase II study and 53 patients
with resected stage II/III melanoma were included in the European
randomized Phase II study.
About Melanoma
According to the American Cancer Society, in 2007 approximately 59,940
new cases are expected to be diagnosed and it is estimated that
approximately 8,110 people in the United Sates will die from the disease.
About IDM Pharma
IDM Pharma (IDM) is a biopharmaceutical company focused on the
development of innovative products that activate the immune system to treat
cancer. IDM's lead product candidate, JUNOVAN(TM) (mifamurtide for
injection), known as MEPACT in Europe, is part of a new family of
immunotherapeutic agents designed to destroy residual cancer cells by
activating the body's natural defenses. IDM's applications requesting
marketing approval of JUNOVAN for use in the treatment of newly diagnosed
resectable high-grade osteosarcoma patients in combination with multiple
agent chemotherapy are under review by the U.S. Food and Drug
Administration, or FDA, in the United States and by the European Medicines
Agency, or EMEA, in Europe. IDM is jointly developing UVIDEM, a cell-based
vaccine product candidate in Phase II clinical trials for the treatment of
melanoma, with sanofi-aventis. EP-2101 is currently being tested in
non-small cell lung cancer (NSCLC) patients in a Phase II clinical trial
and is composed of multiple tumor-specific CTL epitopes selected from
tumor- associated antigens.
For more information, visit http://www.idm-pharma.com.
About sanofi-aventis
Sanofi-aventis is one of the world leaders in the pharmaceutical
industry, ranking number one in Europe. Backed by a world-class R&D
organization, sanofi-aventis is developing leading positions in seven major
therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
diseases, central nervous system, internal medicine and vaccines.
Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE:
SNY).
Forward-Looking Statements
This press release includes and the presentation described in this
press release will include forward-looking statements that reflect
management's current views of future events including statements regarding
the phase II UVIDEM study and the potential for UVIDEM as a treatment for
melanoma, and review of the submissions for marketing approval of JUNOVAN
by the FDA and the EMEA. Actual results may differ materially from the
forward-looking statements due to a number of important factors, including,
but not limited to, the timing of the FDA's and EMEA's review of the
submissions for marketing approval, the ability of the Company to respond
to questions raised by the FDA and EMEA in a satisfactory manner, the time
needed to respond to any issues raised by the FDA and EMEA with regard to
regulatory submissions for JUNOVAN, although the FDA is not bound by the
decision of any advisory panel, the possible negative impact that the
opinion of the FDA's Oncologic Drug Advisory Committee that the results of
the Company's Phase III trial do not provide substantial evidence of
effectiveness of JUNOVAN in the treatment of patients with non-metastatic,
resectable osteosarcoma receiving combination chemotherapy would have upon
the determination by the FDA whether to approve the marketing application
for JUNOVAN, which would have a material and adverse affect on IDM's
business, the possibility that regulatory authorities may not consider
preclinical and early clinical development work conducted by Ciba- Geigy
and efficacy data from the Phase III trial conducted by Children's Oncology
Group as adequate for their assessment of JUNOVAN, which may cause delays
in review, may result in the regulatory authorities requiring the Company
to conduct additional clinical trials, or may result in a determination by
the regulatory authorities that the data does not support marketing
approval, whether regulatory authorities will approve JUNOVAN within the
time frame expected by the Company or at all, and whether the Company will
be able to manufacture JUNOVAN even if it is approved by regulatory
authorities. Other risks affecting the Company and its drug development
programs include whether the Company or any of its collaborators will be
able to develop pharmaceutical products using the technologies of the
Company, whether clinical trial results to date are predictive of results
of any future clinical trials, risks associated with completing clinical
trials of product candidates, risks involved in the regulatory approval
process for the Company's product candidates, the possibility that clinical
testing may reveal undesirable and unintended side effects or other
characteristics that may prevent or limit the commercial use of proposed
products; whether the cash resources of the Company will be sufficient to
fund operations as planned; whether any steps taken by the Company to
contain costs will in fact result in sufficient reduction in expenses;
reliance on key employees, especially senior management; the risk that the
Company may not secure or maintain relationships with collaborators, and
the Company's dependence on intellectual property. These factors are more
fully discussed in the Company's Annual Report on Form 10-Q filed with the
SEC for the quarter ended March 31, 2007 and other periodic reports filed
with the SEC. The Company expressly disclaims any intent or obligation to
update these forward-looking statements, except as required by law.
IDM Pharma, Inc.
http://www.idm-pharma.com
IDM Pharma prezintã rezultate preliminare de la UVIDEM de fazã II (R) Melanoma vaccin studiu clinic - IDM Pharma Presents Preliminary Results From Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial - articole medicale engleza - startsanatate